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Introduction
Over 8000 patients are diagnosed with rectal cancer in the UK
each year1. Treatment has improved over recent years as a result
of incremental advances in optimized surgical technique, clinical
staging, pathological quality control, and multidisciplinary man-
agement2. Neoadjuvant therapy is often required in patients with
locally advanced tumours, and is usually delivered according to a
long-course strategy (long-course radiotherapy, LCRT).
Hypofractionated short-course strategies (short-course radiother-
apy, SCRT) may also be used, traditionally with immediate sur-
gery, but recently have been combined with strategies such as
delayed surgery3,4 and/or systemic chemotherapy5. Such regi-
mens offer potential benefits for patients in terms of reducing
treatment time and access to systemic therapy, but may also be
of use in areas with limited healthcare resources or geographical
access to specialist services5,6.
The COVID-19 pandemic has created a unique situation in the
UK, with multidisciplinary teams balancing the risks of perioper-
ative COVID infection against those of disease progression.
Coupled with altered patient behaviour in accessing healthcare,
constrained diagnostic and critical care facilities, there has been
rapid change in the traditional multimodal treatment strategy
for rectal cancer7. The aim of the prospective ReCaP study was to
follow patients with rectal cancer managed in the UK during the
pandemic, and to determine short-term, long-term, and patient-
reported outcomes. This article presents the short-term results
for the first 500 patients recruited.
Methods
A multicentre, prospective observational study was performed
across the UK from 23 March 2020 (national governmental
lockdown) and is ongoing. The study was performed as a sub-
study of the IMPACT portfolio8 through the Association of
Coloproctology of Great Britain and Ireland. The primary objec-
tive was to determine the short-term clinical and pathological
outcomes associated with each management strategy.
Anonymized data were collected for short-term outcomes and so
ethical approval was not required. Any hospital managing
patients with rectal cancer through a formal multidisciplinary
team (MDT) was eligible for inclusion; rectosigmoid tumours
were excluded.
Results
The first 500 patients were recruited from 42 sites between 23
March 2020 and 28 September 2020. The demographics of the en-
tire cohort are reported in Table S1.
A summary of the initial MDT outcomes for patients, divided
into those diagnosed before the date of national lockdown on an
established treatment pathway versus those diagnosed during
and after the lockdown, is shown in Table 1. A change in MDT pri-
mary outcome owing to COVID-19 was declared for 22.3 per cent
of those with a new diagnosis. The temporal change in treatment
strategy before, during, and after lockdown is illustrated in Fig. 1.
Some 114 patients (22.8 per cent) received neoadjuvant che-
motherapy alone or as part of a radiotherapy regimen. SCRT and
delay increased significantly immediately after commencement
of lockdown (from 15.4 to 45.2 per cent; P< 0.001), dropping back
after its lifting to 19.1 per cent. Fourteen patients received con-
current systemic therapy, with only six (6 per cent) receiving con-
solidation chemotherapy after SCRT. Eight patients (8.2 per cent)
required a stoma before completion of neoadjuvant therapy. At
the time of analysis, only 41 patients (39.4 per cent) had under-
gone surgery after SCRT, with many procedures delayed because
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of COVID-19 restrictions. A total of 158 patients (31.6 per cent) re-
ceived LCRT, and the rate significantly decreased after lockdown
(from 56.3 to 14.0 per cent; P< 0.001). Thirty-three patients (20.9
per cent) required a stoma before completion of LCRT.
To date, 225 patients have undergone surgical resection, 51.6
per cent without any neoadjuvant therapy. Anterior resection
(38.7 per cent) or abdominoperineal resection (25.3 per cent) were
the most common operations performed. There was a signifi-
cantly higher rate of admission to level 2 care after operation be-
fore compared with after lockdown (36.0 versus 10.8 per cent;
P< 0.001). Some 50.3 per cent of operations were performed or
attempted laparoscopically, with a 30-day re-operation rate of 5.8
per cent. Thirty-three patients (14.7 per cent) were deemed to
have had a different operative approach. In 49 patients (21.8 per
cent) a stoma was created owing to COVID-19 alone, and the
overall stomas formation rate was 86.7 per cent. The 30-day mor-
tality rate was 1.3 per cent, with only two patients declared as be-
ing COVID-19-positive within 30 days. A best supportive care
strategy was adopted in 10.2 per cent of the cohort; the rate was
significantly higher in patients diagnosed before lockdown (17.1
versus 0.5 per cent).
A comparison of tumour characteristics, and clinical and
pathological outcomes of patients who underwent SCRT or LCRT,
or proceeded straight to surgery is summarized in Table 2.
Discussion
The COVID-19 pandemic presented unprecedented challenges in
the treatment of rectal cancer. National lockdown, resource
reallocation, and rapidly emerging data showing the unacceptably
high morbidity of perioperative COVID-19 resulted in a sudden and
dramatic change in multimodal management9. Although many of
these COVID-adapted strategies have understandably been under-
taken out of necessity, their safety remains unclear. However, this
dramatic change may offer the potential opportunity for a para-
digm shift in the management of rectal cancer10.
Following national lockdown, 22.3 per cent of patients under-
went a change in initial MDT outcome. There was a rapid shift to
hypofractionated radiotherapy regimens, with SCRT increasing
from 15.4 per cent to 45.2 per cent during the first 8 weeks, and
LCRT dropping from 56.3 per cent to 14.0 per cent. Compared
with recently published national bowel cancer audit (NBOCA)
data, which reports an overall SCRT rate of just 10 per cent, these
rates represent a significant deviation from standard UK practice.
Short-term clinical and pathological outcomes of SCRT appear to
be similar to those of LCRT; however, the omission of systemic che-
motherapy in many of these patients (80.7 per cent) needs to be
monitored carefully5. Some 22.1 per cent of patients entered an ac-
tive monitoring pathway, potentially reflecting the increased rate of
T2 tumours in the LCRT cohort (23.1 versus 5.0 per cent). Although
not all of this cohort underwent surgical resection, the reported
pathological complete response (pCR) rate of 2.9 per cent is much
lower than the pCR rate of 30 per cent in the recently reported
radical surgery versus organ preservation via short-course radiother-
apy followed by transanal endoscopic microsurgery for early-stage
rectal cancer (TREC) study11. Interestingly, the surgical complication
rate was much lower (6.7 per cent) than that in the LCRT group (25.4
per cent) or among those who proceeded directly to surgery (24.1 per
cent). The reasons for this are unclear, but this result is worthy of
note given the potential logistical and geographical benefits SCRT
may offer.
Despite concerns over perioperative COVID-19 infection, there
was perhaps a surprising increase in the number of patients pro-
ceeding straight to surgery. Notably, despite reduced critical care
availability, surgery was still associated with low mortality and
re-operation rates, comparable to NBOCA data (5.8 versus 8.4 per
cent for re-operation). This finding is likely to reflect the rapid
establishment of green, elective ‘ring-fenced’ beds. Despite con-
cerns over viral transmission and aerosolization during laparo-
scopic surgery, 50.3 per cent of procedures were still undertaken
laparoscopically. Reassuringly, although 19.0 per cent of patients
had a threatened circumferential resection margin on preopera-
tive staging, the R1 resection rate was only 3.4 per cent, with 30.7
per cent nodal positivity.
Table 1 Summary of initial multidisciplinary team outcomes for patients with a new diagnosis since 23 March 2020 and on an
existing treatment pathway
Diagnosis before lockdown Diagnosis during or after lockdown Total
(n ¼ 208) (n ¼ 292) (n ¼ 500)
Primary MDT outcome
SCRT 32 (15.4) 82 (28.1) 104 (20.8)
LCRT 117 (56.3) 41 (14.0) 158 (31.6)
Straight to surgery 23 (11.1) 93 (31.8) 116 (23.2)
Organ preservation surgery 3 (1.4) 11 (3.8) 14 (2.8)
Best supportive care 1 (0.5) 50 (17.1) 51 (10.2)
Other 7 (3.4) 13 (4.5) 20 (4.0)
Surgery to metastatic site 1 (0.5) 0 (0) 1 (0.2)
Surveillance 1 (0.5) 6 (2.1) 7 (1.4)
Referral to alternative MDT 5 (2.4) 7 (2.4) 12 (2.4)
Change in plan owing to COVID-19 18 (8.7) 65 (22.3) 83 (16.6)




















Fig. 1 Summary of initial multidisciplinary team outcomes for patients
diagnosed before lockdown, during the first national lockdown, and
after lockdown
LCRT, long-course radiotherapy; SCRT, short-course radiotherapy. *P< 0.005
versus before lockdown (T test).
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The overall rate of best supportive care was 10.2 per cent
across the cohort, but there was significant change between
patients diagnosed after versus before lockdown (17.1 versus
0.5 per cent). The overall rate is lower than the non-operated rate
of 39.7 per cent reported in the NBOCA, but includes patients
with advanced disease. The reasons behind the dramatic change
are unclear, but may represent MDT uncertainty regarding treat-
ment safety and resource allocation12, patient choice, or may re-
late to a more subtle acknowledgement of pessimism in the face
of the pandemic regarding patients who would be considered on
the borders of a curative versus palliative approach.
Limitations of this study include potential site participation,
patient selection, and reporting bias. Some 78.6 per cent of the
cohort had an ASA fitness grade of I–II, potentially highlighting
an under-representation of more vulnerable patients. Cohorts re-
ceiving SCRT and delay and LCRT were non-randomized, with
poor completion of MRI tumour regression grading by clinicians
to enable accurate assessment of radiological response.
This report has demonstrated a rapid and reactive adaptation in
the multimodal management of rectal cancer in the UK in response
to COVID-19. A move to shorten treatment regimens appears to
have been safe in the short term; however, close surveillance should
be undertaken by early imaging and clinical review. Although
patients may have experienced benefit in terms of organ preserva-
tion, and low stoma and complication rates, this has to be balanced
against the significant rise in best supportive care and uncertain
long-term oncological outcomes. The ReCaP study will continue to
monitor this cohort and subsequently managed patients, and pro-
vide further long-term oncological and qualitative outcomes.
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Table 2 Summary of tumour staging, and oncological and pathological outcomes for patients undergoing short-course radiotherapy
and delay, long-course radiotherapy, or straight to surgery
SCRT and delay LCRT Straight to surgery
(n¼104) (n¼158) (n¼116)
Age (years)
< 60 19 (18.3) 53 (33.5) 44 (37.9)
60–80 51 (49.0) 97 (61.4) 72 (62.1)
> 80 64 (61.5) 8 (5.1) 0 (0)
Sex ratio (M : F) 69 : 35 112 : 46 78 : 38
ASA fitness grade
I–II 76 (73.1) 127 (80.4) 100 (86.2)
III–IV 28 (26.9) 29 (18.4) 16 (13.8)
Primary tumour category
T0 0 (0) 0 (0) 0 (0)
T1 0 (0) 3 (1.9) 9 (7.8)
T2 24 (23.1) 8 (5.1) 49 (42.2)
T3 60 (57.7) 91 (58.0) 49 (42.2)
T4 20 (19.2) 56 (35.4) 9 (7.8)
Primary node category
N0 36 (36.0) 28 (17.8) 0 (0)
N1 40 (40.0) 69 (43.9) 8 (6.9)
N2 24 (24.0) 60 (38.2) 0 (0)
Primary metastasis category
M0 93 (89.4) 138 (87.9) 94 (81.0)
M1 11 (10.6) 19 (12.1) 22 (19.0)
Threatened CRM 48 (46.2) 121 (77.0) 22 (19.0)
Tumour height (cm)
Lower (0–6) 56 (53.8) 86 (54.4) 32 (27.6)
Mid (7–11) 35 (33.7) 58 (36.7) 61 (52.6)
Upper (> 12) 13 (12.5) 14 (8.9) 23 (19.8)
Reported surgical complication rate 7 (6.7) 40 (25.4) 28 (24.1)
Radiological outcomes if restaged
Complete clinical response 15 (4.4) 10 (6.3) –
T category regression 36 (34.6) 41 (25.9) –
N category regression 22 (21.5) 46 (29.1) –
T category progression 5 (4.8) 6 (3.8) –
N category progression 4 (3.8) 6 (3.8) –
M category progression 4 (3.8) 14 (8.9) –
Pathological outcomes
Pathological complete response 3 (2.9) 16 (10.1) –
Extramural vascular invasion 7 (6.7) 17 (10.8) 26 (22.4)
Lymphovascular invasion 10 (9.6) 17 (10.8) 27 (23.4)
Perineural invasion 6 (5.8) 13 (8.2) 12 (10.3)
R1 resection 3 (2.9) 9 (5.7) 4 (3.4)
Interval from diagnosis to surgery (days)* 155.5 207 40
Interval from end of radiotherapy to surgery (days)* 86 105 –
Watch and wait 23 (22.1) 19 (12.0) 0 (0)
Best supportive care 5 (4.8) 2 (1.3) 0 (0)
Values in parentheses are percentages unless indicated otherwise; *values are median. SCRT, short-course radiotherapy; LCRT, long-course radiotherapy; CRM,
cirumferential resection margin.
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